Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Belfort – page 8

125 clinical trials in Belfort, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Belfort at a glance
125
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

125 trials in Belfort

Open in trial search

Study on Continuing Nivolumab and Ipilimumab Treatment vs. Observation in Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Study of Atezolizumab, Carboplatin, and Paclitaxel for Elderly Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Daratumumab, and Dexamethasone for Frail Patients with Untreated Multiple Myeloma Not Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Plasma cell myeloma

Not recruiting

Study of Teclistamab with Daratumumab or Lenalidomide for Elderly Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Study on Durvalumab for Patients with Poor General Condition and Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Study of Spartalizumab and Drug Combination for Patients with Metastatic Anal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Centre Hospitalier Regional Universitaire

Study Comparing Radiotherapy Alone to Radiotherapy with Cisplatin for Patients with Sinus or Salivary Gland Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bayer AG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Belfort

What the registry says about research in the country

01 Respiratory and Circulatory Physiology

The clinical research activity in Belfort focuses on a small but clearly targeted set of studies within Phenomena and Processes, especially Circulatory and Respiratory Physiological Phenomena. These trials are examining how treatments may improve patient outcomes in serious lung and blood-circulation-related conditions.

  • Research in Chronic pulmonary aspergillosis is assessing better control of persistent fungal lung disease
  • Studies in Septic shock are exploring ways to support critically ill patients with severe circulatory failure
  • Clinical work is aimed at comparing treatment effectiveness and improving patient survival and recovery

This area brings together respiratory and intensive care research, with a focus on evaluating whether new or combined approaches can provide stronger clinical benefit than standard care alone.

02 Pulmonary Infection and Antifungal Care

One line of research is centered on Chronic pulmonary aspergillosis, a long-term fungal infection affecting the lungs. The studies are designed to test whether adding another therapy can improve both clinical response and imaging results in patients with limited immune suppression.

  • Focus on persistent fungal lung infection and treatment response
  • Evaluation of whether combination therapy offers added benefit over standard antifungal care
  • Interest in both symptom improvement and radiological outcomes

These trials help clarify how best to manage a difficult respiratory condition where long-term control is often a challenge.

03 Critical Care and Septic Shock Research

Another study area examines Septic shock in mechanically ventilated patients, with attention on treatments that may improve outcomes in severe, refractory cases. The goal is to see whether an added supportive therapy can reduce mortality alongside standard critical care.

  • Research on severe infection-related shock and organ support
  • Assessment of adjunctive treatment for patients not responding well to usual care
  • Outcome focus on short-term survival in intensive care settings

This work supports efforts to strengthen treatment strategies for one of the most urgent emergencies in intensive care medicine.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.